Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection
dc.contributor.author | Przyklenk, Karin | |
dc.contributor.author | Maynard, Michelle | |
dc.contributor.author | Darling, Chad E. | |
dc.contributor.author | Whittaker, Peter | |
dc.date | 2022-08-11T08:09:33.000 | |
dc.date.accessioned | 2022-08-23T16:35:41Z | |
dc.date.available | 2022-08-23T16:35:41Z | |
dc.date.issued | 2005-05-28 | |
dc.date.submitted | 2009-03-26 | |
dc.identifier.citation | J Pharmacol Exp Ther. 2005 Sep;314(3):1386-92. Epub 2005 May 26. <a href="http://dx.doi.org/10.1124/jpet.105.087742">Link to article on publisher's site</a> | |
dc.identifier.issn | 0022-3565 (Print) | |
dc.identifier.doi | 10.1124/jpet.105.087742 | |
dc.identifier.pmid | 15919762 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/38614 | |
dc.description.abstract | Pretreatment with D-myo-inositol-1,4,5-trisphosphate hexasodium (D-myo-IP(3)), the sodium salt of the second messenger inositol 1,4,5-trisphosphate (IP(3)), is cardioprotective and triggers a reduction of infarct size comparable in magnitude to that obtained with ischemic preconditioning. However, this observation is enigmatic; whereas IP(3) signaling is conventionally initiated by receptor binding, IP(3) receptors are typically considered to be intracellular, and D-myo-IP(3) is membrane-impermeable. We propose that this paradox is explained by the presence of poorly characterized external IP(3) receptors and hypothesize that: 1) infarct size reduction with D-myo-IP(3) is receptor-mediated; and 2) communication via gap junctions and/or hemichannels is required to initiate this protection. To investigate the role of receptor binding, isolated buffer-perfused rabbit hearts underwent 30 min of coronary occlusion (CO) and 2 h of reflow. Prior to CO, hearts received no treatment (controls), D-myo-IP(3), L-myo-IP(3) (enantiomer not recognized by the IP(3) receptor), D-myo-IP(3) + the IP(3) receptor inhibitor xestospongin C (XeC), or XeC alone. Infarct size, assessed by tetrazolium staining, was reduced with D-myo-IP(3) treatment, whereas hearts that received L-myo-IP(3) or D-myo-IP(3) + XeC showed no protection. To evaluate the contribution of gap junctions/hemichannels, additional control and D-myo-IP(3)-treated cohorts received a 5-min infusion of heptanol or Gap 27, two structurally distinct gap junction inhibitors, administered at doses confirmed to attenuate intercellular transmission of a gap junction-permeable fluorescent dye. There was no infarct-sparing effect of D-myo-IP(3) in inhibitor-treated hearts. These data support the concepts that infarct size reduction with D-myo-IP(3) is triggered by receptor binding and that communication via gap junctions/hemichannels is involved in initiating this protection. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=15919762&dopt=Abstract">Link to Article in PubMed</a> | |
dc.relation.url | http://dx.doi.org/10.1124/jpet.105.087742 | |
dc.subject | Animals | |
dc.subject | Calcium Channels | |
dc.subject | Gap Junctions | |
dc.subject | Inositol 1,4,5-Trisphosphate | |
dc.subject | Inositol 1,4,5-Trisphosphate Receptors | |
dc.subject | Myocardial Infarction | |
dc.subject | Rabbits | |
dc.subject | Receptors, Cytoplasmic and Nuclear | |
dc.subject | Life Sciences | |
dc.subject | Medicine and Health Sciences | |
dc.title | Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection | |
dc.type | Journal Article | |
dc.source.journaltitle | The Journal of pharmacology and experimental therapeutics | |
dc.source.volume | 314 | |
dc.source.issue | 3 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/1477 | |
dc.identifier.contextkey | 798452 | |
html.description.abstract | <p>Pretreatment with D-myo-inositol-1,4,5-trisphosphate hexasodium (D-myo-IP(3)), the sodium salt of the second messenger inositol 1,4,5-trisphosphate (IP(3)), is cardioprotective and triggers a reduction of infarct size comparable in magnitude to that obtained with ischemic preconditioning. However, this observation is enigmatic; whereas IP(3) signaling is conventionally initiated by receptor binding, IP(3) receptors are typically considered to be intracellular, and D-myo-IP(3) is membrane-impermeable. We propose that this paradox is explained by the presence of poorly characterized external IP(3) receptors and hypothesize that: 1) infarct size reduction with D-myo-IP(3) is receptor-mediated; and 2) communication via gap junctions and/or hemichannels is required to initiate this protection. To investigate the role of receptor binding, isolated buffer-perfused rabbit hearts underwent 30 min of coronary occlusion (CO) and 2 h of reflow. Prior to CO, hearts received no treatment (controls), D-myo-IP(3), L-myo-IP(3) (enantiomer not recognized by the IP(3) receptor), D-myo-IP(3) + the IP(3) receptor inhibitor xestospongin C (XeC), or XeC alone. Infarct size, assessed by tetrazolium staining, was reduced with D-myo-IP(3) treatment, whereas hearts that received L-myo-IP(3) or D-myo-IP(3) + XeC showed no protection. To evaluate the contribution of gap junctions/hemichannels, additional control and D-myo-IP(3)-treated cohorts received a 5-min infusion of heptanol or Gap 27, two structurally distinct gap junction inhibitors, administered at doses confirmed to attenuate intercellular transmission of a gap junction-permeable fluorescent dye. There was no infarct-sparing effect of D-myo-IP(3) in inhibitor-treated hearts. These data support the concepts that infarct size reduction with D-myo-IP(3) is triggered by receptor binding and that communication via gap junctions/hemichannels is involved in initiating this protection.</p> | |
dc.identifier.submissionpath | oapubs/1477 | |
dc.contributor.department | Department of Emergency Medicine | |
dc.source.pages | 1386-92 |